113201-61-9Relevant articles and documents
(+)-5-isopropyl 3-methyl 2-cyano-6 methyl-4-(3-nitrophenyl)-1, 4-dihydropyridine-3, 5-dicarboxylate
-
, (2008/06/13)
This invention relates to novel (+)-5-isopropyl 3-methyl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate. More particularly, it relates to novel (+)-5-isopropyl 3-methyl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, which has pharmacological activities such as hypotensive and vasodilating activities, to a pharmaceutical composition comprising the same and to a method for treating hypertension, cardiovascular diseases, and the like. Accordingly, one object of this invention is to provide novel (+)-5-isopropyl 3-methyl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, which is of use for treating hyperxtension, cardiovascular diseases, and the like.
Studies on nilvadipine. III. Synthesis of metabolites of nilvadipine and their related compounds
Satoh,Okumura,Shiokawa
, p. 1799 - 1807 (2007/10/02)
Nilvadipine (I), isopropyl 2-cyano-3-methoxycarbonyl-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridi ne-5-carboxylate, has a unique 1,4-dihydropyridine structure in that the substituents at all five positions of the nucleus differ from one another. It is an exellent calcium antagonist drug in terms of its potency, its duration of action and its selectivity in the blood vascular system. During the development of I, some metabolites were isolated from the urine and bile of both rats and dogs after oral administration. With data obtained from the metabolism of known 1,4-dihydropyridines at hand, we proposed the synthesis of a series of compounds (1-11) for comparison with the metabolites isolated from I as a method for structure determination. Indeed, of the compounds synthesized five of them (3-7) were found to coincide with the metabolites from both rat and dog urine and bile isolates.
